Abbvie also has a combo that should be approved by the end of the year.
AbbVie Oral Regimen Cures Nearly All GT1 Hepatitis C, Phase 3 Trials Now Done
AbbVie announced this week that it has completed Phase 3 clinical trials of its interferon-free regimen containing 3 direct-acting antivirals, with or without ribavirin, for the treatment of chronic hepatitis C. Across all studies, between 90% and 100% of participants achieved sustained virological response, usually with 12 weeks of therapy, including hard-to-treat patient groups such as people with HCV subtype 1a and liver cirrhosis.
AbbVie previously announced findings from the SAPPHIRE-I and SAPPHIRE-II trials, which both produced 96% overall sustained response rates at 12 weeks post-treatment (SVR12) using a 4-drug regimen consisting of the HCV protease inhibitor ABT-450, the NS5A inhibitor ABT-267, the non-nucleoside polymerase inhibitor ABT-333, and ribavirin
Since then, the PEARL-II, -III, and -IV trials have shown that a 3-drug regimen without ribavirin for 12 weeks cures 99%-100% of patients with HCV subtype 1b, but adding ribavirin is more effective for those with harder-to-treat subtype 1a. The TURQUOISE-II study showed that the quadruple regimen for 12 or 24 weeks cures most people with compensated liver cirrhosis.
AbbVie plans to submit data from these trials to the U.S. Food and Drug Administration in the second quarter of 2014, putting the designated "breakthrough therapy" on track for approval by the end of the year.
http://hivandhepatitis.com/hcv-treatment/experimental-hcv-drugs/4507-abbvie-all-oral-regimen-cures-nearly-all-gt1-hepatitis-c-phase-3-trials-now-complete
i want to see if i can find the ION info..
thanks.. information is always good..
A couple more in the pipeline: daclatasvir (DCV) and asunaprevir (ASV)
http://news.bms.com/press-release/bristol-myers-squibb-receives-us-fda-breakthrough-therapy-designation-all-oral-daclata
Here is one in the pipeline for genotype 1:
http://www.gilead.com/news/press-releases/2014/2/gilead-files-for-us-approval-of-ledipasvirsofosbuvir-fixeddose-combination-tablet-for-genotype-1-hepatitis-c
Nan